NEW YORK (GenomeWeb) – Toronto-based ChipCare is developing a microfluidic diagnostic platform that works similarly to a flow cytometer, but will be made available at a fraction of the cost and size.

The firm, a 2009 spinout from the University of Toronto, expects to make available a rugged, hand held system at the point of patient care, and expects to have a CE-marked HIV-related diagnostic test on the market in Africa around the end of 2017.